WO2004103271A3 - Prevention de maladies et vaccination avant reactivation thymique - Google Patents

Prevention de maladies et vaccination avant reactivation thymique Download PDF

Info

Publication number
WO2004103271A3
WO2004103271A3 PCT/US2004/011921 US2004011921W WO2004103271A3 WO 2004103271 A3 WO2004103271 A3 WO 2004103271A3 US 2004011921 W US2004011921 W US 2004011921W WO 2004103271 A3 WO2004103271 A3 WO 2004103271A3
Authority
WO
WIPO (PCT)
Prior art keywords
lhrh
patient
thymic
selective
reactivations
Prior art date
Application number
PCT/US2004/011921
Other languages
English (en)
Other versions
WO2004103271A2 (fr
Inventor
Gabrielle Lianne Goldberg
Jayne Suzanne Sutherland
Ann Patricia Chidgey
Richard Boyd
Original Assignee
Norwood Immunology Ltd
Gabrielle Lianne Goldberg
Jayne Suzanne Sutherland
Ann Patricia Chidgey
Richard Boyd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/419,068 external-priority patent/US20050002913A1/en
Priority claimed from US10/418,747 external-priority patent/US20040018180A1/en
Priority claimed from US10/418,727 external-priority patent/US20040013641A1/en
Priority claimed from US10/419,066 external-priority patent/US20040037817A1/en
Priority claimed from US10/749,118 external-priority patent/US20040265285A1/en
Priority claimed from US10/748,450 external-priority patent/US20040241842A1/en
Priority claimed from US10/749,122 external-priority patent/US20040259803A1/en
Priority claimed from US10/748,831 external-priority patent/US20050020524A1/en
Priority to CA002528521A priority Critical patent/CA2528521A1/fr
Priority to JP2006532426A priority patent/JP2007518699A/ja
Priority to US10/553,594 priority patent/US20080279812A1/en
Priority to EP04785486A priority patent/EP1620126A4/fr
Priority to AU2004241949A priority patent/AU2004241949A1/en
Application filed by Norwood Immunology Ltd, Gabrielle Lianne Goldberg, Jayne Suzanne Sutherland, Ann Patricia Chidgey, Richard Boyd filed Critical Norwood Immunology Ltd
Publication of WO2004103271A2 publication Critical patent/WO2004103271A2/fr
Publication of WO2004103271A3 publication Critical patent/WO2004103271A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/46447—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4647—Protozoa antigens
    • A61K39/464714—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/464817—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464839—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)

Abstract

L'invention concerne des méthodes de prévention ou de traitement de maladies, permettant d'améliorer la faculté de réponse aux vaccinations et d'améliorer l'efficacité de la thérapie génique chez des patients, par interruption de la signalisation de stéroïdes sexuels chez un patient. Selon l'invention, la fonctionnalité de la moelle osseuse et celle d'autres cellules immunitaires sont améliorées, sans régénération thymique préalable ou simultanée. Dans certains modes de réalisation, la signalisation des stéroïdes sexuels est interrompue ou supprimée chez le patient concerné, par administration d'agonistes de la LHRH, d'antagonistes de la LHRH, d'anticorps du récepteur anti-LHRH, de vaccins anti-LHRH, d'anti-androgènes, d'anti-oestrogènes, de modulateurs sélectifs du récepteur d'oestrogènes (SERM), de modulateurs sélectifs du récepteur d'androgènes (SARM), de modulateurs sélectifs de réponse à la progestérone (SPRM), d'ERD, d'inhibiteurs d'aromatase ou de différentes combinaisons des constituants précités.
PCT/US2004/011921 2003-04-18 2004-04-19 Prevention de maladies et vaccination avant reactivation thymique WO2004103271A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2004241949A AU2004241949A1 (en) 2003-04-18 2004-04-19 Disease prevention and vaccination prior to thymic reactivations
EP04785486A EP1620126A4 (fr) 2003-04-18 2004-04-19 Prevention de maladies et vaccination avant reactivation thymique
US10/553,594 US20080279812A1 (en) 2003-12-05 2004-04-19 Disease Prevention and Vaccination Prior to Thymic Reactivation
JP2006532426A JP2007518699A (ja) 2003-04-18 2004-04-19 胸腺再生前の病気の予防およびワクチン接種
CA002528521A CA2528521A1 (fr) 2003-04-18 2004-04-19 Prevention de maladies et vaccination avant reactivation thymique

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US10/419,068 US20050002913A1 (en) 1999-04-15 2003-04-18 Hematopoietic stem cell gene therapy
US10/419,066 US20040037817A1 (en) 1999-04-15 2003-04-18 Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US10/418,727 US20040013641A1 (en) 1999-04-15 2003-04-18 Disease prevention by reactivation of the thymus
US10/419,066 2003-04-18
US10/418,747 2003-04-18
US10/419,068 2003-04-18
US10/418,727 2003-04-18
US10/418,747 US20040018180A1 (en) 1999-04-15 2003-04-18 Stimulation of thymus for vaccination development
US52700103P 2003-12-05 2003-12-05
US60/527,001 2003-12-05
US10/749,118 US20040265285A1 (en) 1999-04-15 2003-12-30 Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US10/749,118 2003-12-30
US10/749,122 2003-12-30
US10/748,450 2003-12-30
US10/748,450 US20040241842A1 (en) 1999-04-15 2003-12-30 Stimulation of thymus for vaccination development
US10/748,831 2003-12-30
US10/749,122 US20040259803A1 (en) 1999-04-15 2003-12-30 Disease prevention by reactivation of the thymus
US10/748,831 US20050020524A1 (en) 1999-04-15 2003-12-30 Hematopoietic stem cell gene therapy

Publications (2)

Publication Number Publication Date
WO2004103271A2 WO2004103271A2 (fr) 2004-12-02
WO2004103271A3 true WO2004103271A3 (fr) 2005-11-24

Family

ID=33314639

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2004/011921 WO2004103271A2 (fr) 2003-04-18 2004-04-19 Prevention de maladies et vaccination avant reactivation thymique
PCT/US2004/011913 WO2004094599A2 (fr) 2003-04-18 2004-04-19 Prvention contre une maladie et vaccination apres reactivation thymique

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011913 WO2004094599A2 (fr) 2003-04-18 2004-04-19 Prvention contre une maladie et vaccination apres reactivation thymique

Country Status (6)

Country Link
EP (2) EP1620126A4 (fr)
JP (1) JP2007518699A (fr)
KR (1) KR20060022232A (fr)
AU (1) AU2004241949A1 (fr)
CA (1) CA2528521A1 (fr)
WO (2) WO2004103271A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1620126A4 (fr) * 2003-04-18 2007-07-04 Norwood Immunology Ltd Prevention de maladies et vaccination avant reactivation thymique
CN100425288C (zh) * 2005-01-28 2008-10-15 北京金迪克生物技术研究所 鼻腔喷雾型流感病毒灭活疫苗及其制备方法
GB0519303D0 (en) * 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
AU2009240738B2 (en) 2008-04-21 2014-09-11 Tissue Regeneration Therapeutics, Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
US20110144032A1 (en) * 2008-08-08 2011-06-16 Christopher Hovens Biological applications of steroid binding domains
US20110086051A1 (en) * 2009-10-08 2011-04-14 Dartmouth-Hitchcock Clinic System and method for monitoring and optimizing immune status in transplant recipients
JP2016509571A (ja) * 2012-10-15 2016-03-31 チャマエレオ ファーマ ビーブイビーエー 雌哺乳動物でのがんの根治的又は対症的処置における使用のためのホスフェストロール
WO2018134373A1 (fr) * 2017-01-20 2018-07-26 Immune System Regulation Holding Ab Nouveaux composés (immunorhelines - infections intracellulaires)
KR20190117541A (ko) 2017-01-20 2019-10-16 이뮨 시스템 레귤레이션 홀딩 에이비 신규 화합물 (이뮤노렐린)
EP3585414A1 (fr) 2017-02-22 2020-01-01 Immune System Regulation Holding AB Hormones de libération des gonadotropines destinées à être utilisées en tant qu'adjuvants immunothérapeutiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062657A2 (fr) * 1999-04-15 2000-10-26 Monash University Amelioration de l'immunite induite par les lymphocytes t
WO2002031110A2 (fr) * 2000-10-13 2002-04-18 Monash University Therapie genique aux cellules souches hematopoietiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20020086000A1 (en) * 1999-04-15 2002-07-04 Richard Boyd Stimulation of thymus for vaccination development
BR0114642A (pt) * 2000-10-13 2004-01-20 Univ Monash Prevenção de doenças através da reativação do timo
EP1620126A4 (fr) * 2003-04-18 2007-07-04 Norwood Immunology Ltd Prevention de maladies et vaccination avant reactivation thymique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062657A2 (fr) * 1999-04-15 2000-10-26 Monash University Amelioration de l'immunite induite par les lymphocytes t
WO2002031110A2 (fr) * 2000-10-13 2002-04-18 Monash University Therapie genique aux cellules souches hematopoietiques

Also Published As

Publication number Publication date
EP1620545A2 (fr) 2006-02-01
JP2007518699A (ja) 2007-07-12
CA2528521A1 (fr) 2004-12-02
AU2004241949A1 (en) 2004-12-02
WO2004103271A2 (fr) 2004-12-02
KR20060022232A (ko) 2006-03-09
EP1620126A2 (fr) 2006-02-01
WO2004094599A2 (fr) 2004-11-04
EP1620545A4 (fr) 2007-07-04
WO2004094599A3 (fr) 2005-12-29
EP1620126A4 (fr) 2007-07-04

Similar Documents

Publication Publication Date Title
Ruddell et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis
WO2004103271A3 (fr) Prevention de maladies et vaccination avant reactivation thymique
Araújo et al. Importance of vascular endothelial growth factor (VEGF) in ovarian physiology of mammals
El-Sakka et al. Effects of diabetes on nitric oxide synthase and growth factor genes and protein expression in an animal model
EA202091816A1 (ru) Способ доставки лекарственного средства в мышцу
Schulman et al. Reversibility of the effects of GnRH‐vaccination used to suppress reproductive function in mares
EP4360639A3 (fr) Variants de surface cellulaire discernables immunologiquement destinés à être utilisés en thérapie cellulaire
AU2003284390A1 (en) Electrotherapy system, device, and method for treatment of cardiac valve dysfunction
WO2004004633A3 (fr) Utilisation d'anticorps anti-tnf$g(a) et d'un autre produit pharmaceutique
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
WO2002015920A3 (fr) Traitement des maladies d'hyperproliferation
NO20055187L (no) Fremgangsmate for behandling og forebygging av lavere urinkanal symptomer
Goto et al. Ovarian and Hormonal Responses to Follicular Phase Administration of Investigational Metastin/Kisspeptin Analog, TAK‐683, in Goats
JP2018087193A (ja) 対象における慢性または解決不能な疼痛を処置するための、および／または痛覚閾値を高めるための方法、およびこれに用いる医薬組成物
Ising et al. Stress response regulation in panic disorder
WO2004094988A3 (fr) Tolerance a implant avant la regeneration thymique
WO2005069935A3 (fr) Procedes de mesure de l'activite de signalisation du recepteur du facteur de croissance transformant beta (tgf-$g(b)) et utilisation desdits procedes
JP2004523730A (ja) 胸腺機能診断用インジケーター
Manes et al. Influence of the length of progestagen treatment and the time of oestradiol benzoate application on the ovulatory follicle size and ovulation time in anoestrous and cyclic beef cows
Prajapati et al. Influence of Estrus Synchronization Protocols on Plasma Profile of Progesterone, Protein and Cholesterol in Acyclic HF Crossbred Cows.
WO2005101000A3 (fr) Superagonistes de l'hormone glycoproteine humaine et utilisations
Dean et al. Neuroregenerative strategies after radical prostatectomy
Bochenek et al. The Toll-like receptors mRNA expression profile in the pineal gland of sheep during long and short days
Sudano et al. Reuse of norgestomet implants in an eCG-based superovulation protocol administered to Nelore (Bos taurus indicus) cows
El-Sakka et al. Possible molecular mechanisms of cryoablation-induced impotence in a rat model

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006532426

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057019858

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004785486

Country of ref document: EP

Ref document number: 2005/09362

Country of ref document: ZA

Ref document number: 2004241949

Country of ref document: AU

Ref document number: 2005135856

Country of ref document: RU

Ref document number: 200509362

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2528521

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004241949

Country of ref document: AU

Date of ref document: 20040419

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004241949

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20048170651

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004785486

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057019858

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10553594

Country of ref document: US